Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy.
Howe, M C Chapman, A Kerr, K Dougal, Mark Anderson, Heather Hasleton, Philip S
Howe, M C
Chapman, A
Kerr, K
Dougal, Mark
Anderson, Heather
Hasleton, Philip S
Citations
Altmetric:
Abstract
AIMS: Histopathologists report the presence of neuroendocrine (NE) differentiation in non-small cell lung carcinoma (NSCLC) in up to a third of cases and are often questioned about its clinical relevance. The conclusions of previous studies have been inconsistent. This paper aims to provide an answer by examining a large series together with a comprehensive critique of the literature. METHODS AND RESULTS: Four hundred and thirty-nine cases of NSCLC were examined, immunohistochemically, using antibodies to chromogranin A (CGA), synaptophysin (SYN) and CD56/neural cell adhesion molecule (NCAM). Three hundred and forty-one cases had been treated with surgical resection and the remainder with chemotherapy. The results were compared with clinical outcome. Thity-six percent of cases had positive staining for at least one NE marker. CGA was positive in 5.5% of cases, SYN in 16.5% and NCAM in 28%. There was no association between the presence of NE markers and survival in either the surgically treated group or the chemotherapy-treated group. There was also no association between NE markers and response to chemotherapy in the latter group. CONCLUSIONS: The presence of immunohistochemically detected NE differentiation in NSCLC is not of prognostic significance.
Description
Date
2005-02
Publisher
Collections
Keywords
Lung Cancer
Type
Article
Citation
Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. 2005, 46 (2):195-201 Histopathology